TABLE 4.
Adjusted ORs and 95% CIs for Early Discontinuation (N = 26,098)
| Covariates | Adjusted OR | 95% CI |
|---|---|---|
| Drug regimen | ||
| OPrD | Reference | – |
| SIM/SOF | 0.53 | 0.37-0.74 |
| LDV/SOF | 0.31 | 0.25-0.38 |
| SOF/VEL | 0.26 | 0.19-0.37 |
| EBR/GZR | 0.33 | 0.23-0.47 |
| GLE/PIB | 0.18 | 0.07-0.46 |
| Use of ribavirin during follow-up | 1.12 | 0.91-1.37 |
| Age (5-year increments) | 0.92 | 0.89-0.95 |
| Sex (female vs. male) | 1.17 | 1.03-1.33 |
| Year of cohort entry | ||
| 2014 | Reference | – |
| 2015 | 0.74 | 0.57-0.95 |
| 2016 | 0.62 | 0.48-0.82 |
| 2017 | 0.71 | 0.53-0.95 |
| Health plan coverage | ||
| Commercial plans | Reference | – |
| Medicare | 1.63 | 1.30-2.05 |
| Medicaid | 1.55 | 1.34-1.78 |
| Cirrhosis | 1.03 | 0.87-1.22 |
| Anemia | 1.27 | 1.03-1.56 |
| Diabetes | 1.17 | 0.99-1.38 |
| HIV infection | 1.14 | 0.76-1.72 |
| Charlson Comorbidity Index | 1.01 | 0.97-1.05 |
| Drug abuse | 1.16 | 0.93-1.45 |
| Alcohol abuse | 1.12 | 0.89-1.41 |
| Number of physician visits | 1.00 | 1.00-1.01 |
| Number of ED visits | 1.02 | 1.00-1.04 |
| Number of hospitalizations | 1.04 | 0.97-1.11 |
CI = confidence interval; EBR/GZR = elbasvir/grazoprevir; ED = emergency department; GLE/PIB = glecaprevir/pibrentasvir; HIV = human immunodeficiency virus; LDV/SOF = ledipasvir/sofosbuvir; OPrD = ombitasvir/paritaprevir/ritonavir + dasabuvir; OR = odds ratio; SIM/SOF = simeprevir/sofosbuvir; SOF/VEL = sofosbuvir/velpatasvir.